Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1

被引：74

作者：

Ballou, WR

Reed, JL

Noble, W

Young, NS

Koenig, S

机构：

[1] Medimmune Inc, Gaithersburg, MD 20878 USA

[2] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2003年 / 187卷 / 04期

关键词：

D O I：

10.1086/368382

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n = 24) received either 2.5 or 25 mug MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.

引用

收藏

页码：675 / 678

页数：4

相关论文

共 15 条

[1] HUMAN PARVOVIRUS INFECTION IN PREGNANCY AND HYDROPS-FETALIS [J].

ANAND, A ;

GRAY, ES ;

BROWN, T ;

CLEWLEY, JP ;

COHEN, BJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (04) :183-186

[2] Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase polymerase chain reaction based assay [J].

Bostic, JR ;

Brown, KE ;

Young, NS ;

Koenig, S .

JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (03) :619-626

[3] MOLECULAR, CELLULAR AND CLINICAL ASPECTS OF PARVOVIRUS B19 INFECTION [J].

BROWN, KE ;

YOUNG, NS ;

LIU, JM .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1994, 16 (01) :1-31

[4]

Chernoff D, 1995, VACCINE DESIGN SUBUN, P277

[5]

KAIJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646

[6] HUMAN-SERUM PARVOVIRUS - A SPECIFIC CAUSE OF APLASTIC CRISIS IN CHILDREN WITH HEREDITARY SPHEROCYTOSIS [J].

KELLEHER, JF ;

LUBAN, NLC ;

MORTIMER, PP ;

KAMIMURA, T .

JOURNAL OF PEDIATRICS, 1983, 102 (05) :720-722

[7]

KOMATSU N, 1993, BLOOD, V82, P456

[8] Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza [J].

Nicholson, KG ;

Colegate, AE ;

Podda, A ;

Stephenson, I ;

Wood, J ;

Ypma, E ;

Zambon, MC .

LANCET, 2001, 357 (9272) :1937-1943

[9] A phase I/II trial of HIVSF2 gp120/MF59 vaccine in seronegative Thais [J].

Nitayaphan, S ;

Khamboonruang, C ;

Sirisophana, N ;

Morgan, P ;

Chiu, J ;

Duliege, AM ;

Chuenchitra, C ;

Supapongse, T ;

Rungruengthanakit, K ;

deSouza, M ;

Mascola, JR ;

Boggio, K ;

Ratto-Kim, S ;

Markowitz, LE ;

Birx, D ;

Suriyanon, V ;

McNeil, JG ;

Brown, AE ;

Michael, RA .

VACCINE, 2000, 18 (15) :1448-1455

[10] NOVEL TRANSCRIPTION MAP FOR THE B19 (HUMAN) PATHOGENIC PARVOVIRUS [J].

OZAWA, K ;

AYUB, J ;

HAO, YS ;

KURTZMAN, G ;

SHIMADA, T ;

YOUNG, N .

JOURNAL OF VIROLOGY, 1987, 61 (08) :2395-2406